{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-011990","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.682133+00:00","generated_at":"2026-05-15T23:25:39.943917+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Collegium Q4 net rev $205.4M (+13% YoY); FY 2025 rev $780.6M (+24%); reaffirms 2026 guidance","bullets":["Q4 GAAP diluted EPS $0.46 vs $0.36 YoY; adjusted diluted EPS $2.04 vs $1.77.","Jornay PM Q4 net revenue $45.9M (+57%); full-year $148.9M (+48%).","Pain portfolio FY 2025 net revenue $631.7M (+6%); Belbuca $221.7M (+5%).","Full-year adjusted EBITDA $460.5M (+15%); cash & marketable securities $386.7M.","Closed $980M credit facility in Dec; repurchased $25M shares in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-011990","json":"https://secwatch.observer/filing/0001628280-26-011990.json","markdown":"https://secwatch.observer/filing/0001628280-26-011990.md","text":"https://secwatch.observer/filing/0001628280-26-011990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000162828026011990/0001628280-26-011990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000162828026011990/coll-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:25:39.943917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}